-
Mashup Score: 1
Androgen deprivation therapy (ADT) combined with apalutamide, abiraterone acetate plus prednisone, enzalutamide, or docetaxel are the standard treatments for advanced castration-sensitive prostate cancer (CSPC). We investigated ADT-free alternatives for advanced CSPC.
Source: European Journal of CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Androgen deprivation therapy (ADT) combined with apalutamide, abiraterone acetate plus prednisone, enzalutamide, or docetaxel are the standard treatments for advanced castration-sensitive prostate cancer (CSPC). We investigated ADT-free alternatives for advanced CSPC.
Source: European Journal of CancerCategories: Latest Headlines, UrologyTweet-
https://t.co/4mVaXh9Uwb Here are the data
-
-
Mashup Score: 1Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study - 2 year(s) ago
IMbrave150 has established the superiority of atezolizumab plus bevacizumab over sorafenib in patients with unresectable hepatocellular carcinoma (HCC).
Source: European Journal of CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
@NiuSanford @flatironhealth @tjroycemd @DusetzinaS Although @FulgenziClaudia found mOS of 15 months in their prospective real world analysis of atezo bev in HCC https://t.co/L2wo2w0OL0 Will need to be followed closely in the coming years!
-
-
Mashup Score: 0Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study - 2 year(s) ago
IMbrave150 has established the superiority of atezolizumab plus bevacizumab over sorafenib in patients with unresectable hepatocellular carcinoma (HCC).
Source: European Journal of CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Since initiating this study, several other similar papers have been published on the topic, perhaps topped by really elegant work by @FulgenziClaudia and colleagues with similar conclusions published in EJC here: https://t.co/L2wo2w0OL0
-
-
Mashup Score: 9
Although optimizing rectal cancer treatment has reduced local recurrence rates, many patients develop distant metastases (DM). The current study investigated whether a total neoadjuvant treatment strategy influences the development, location, and timing of metastases in patients diagnosed with high-risk locally advanced rectal cancer included in the RAPIDO trial.
Source: European Journal of CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
RAPIDO trial showed that TNT reduces the risk of liver metastasis compared to the standard approach! @DFarberYoungCRC @OncoAlert @OncologyAdvance https://t.co/HwBoGWU5tJ
-
-
Mashup Score: 0
This multicenter phase 2 trial evaluated the safety and efficacy of osimertinib and platinum-based chemotherapy (OPP) in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer (NSCLC).
Source: European Journal of CancerCategories: Latest Headlines, Oncologists2Tweet-
Out in EJC the full 📄 of the Japan Ph2 trial of Osimertinib in combo with Platinum & Pemetrexed, in 67 pts with naïve #lungcancer with EGFR comm mut’s: the OPAL trial ▪️ORR: 90.9% ▪️mPFS: 31.0 months ▪️mOS: not reached Carbo better then Cisp 🔗https://t.co/iiKkadQaij Waiting… https://t.co/mNvLcRlRY2 https://t.co/psz57ayYfz
-
-
Mashup Score: 3Uptake of COVID-19 vaccination in people with blood cancer: Population-level cohort study of 12 million patients in England - 2 year(s) ago
People with blood cancers have increased risk of severe outcomes from COVID-19 and were prioritised for vaccination.
Source: European Journal of CancerCategories: Expert Picks, Latest HeadlinesTweet-
COVID vaccines: Uptake of COVID-19 vaccination in people with blood cancer (12 million patients UK). Most of world (WHO recs) settling on plan to only boost those who are older or on immunosuppressants once yearly; hope to increase uptake in these groups https://t.co/4jDnacYuBZ
-
-
Mashup Score: 7Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population - 2 year(s) ago
Atezolizumab plus bevacizumab and lenvatinib have not been compared in a randomised controlled trial. We conducted a retrospective multi-centre study to compare the clinical efficacy and safety of lenvatinib and atezolizumab with bevacizumab as a first-line treatment for patients with unresectable HCC in the real-world scenario.
Source: European Journal of CancerCategories: Latest Headlines, Oncologists2Tweet-
RT @DucreuxMichel: Real life data about the use of atezolizumab bevacizumab in advanced hepatocellular cancer https://t.co/hwVpoNswFC
-
-
Mashup Score: 0Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12 - 2 year(s) ago
The widespread adoption of adjuvant bisphosphonate therapy for postmenopausal early breast cancer (EBC) patients was based on results of the Early Breast Cancer Trialist Group (EBCTCG) meta-analysis. Despite multiple regimens evaluated, there was no signal of varying efficacy with type, dose/dose intensity of bisphosphonate administration. We evaluated the effect of early treatment cessation…
Source: European Journal of CancerCategories: Latest Headlines, Oncologists2Tweet-
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12 - European Journal of Cancer via @BreastDocUK #less is more https://t.co/4v4BNaUXKV
-
-
Mashup Score: 1Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12 - 2 year(s) ago
The widespread adoption of adjuvant bisphosphonate therapy for postmenopausal early breast cancer (EBC) patients was based on results of the Early Breast Cancer Trialist Group (EBCTCG) meta-analysis. Despite multiple regimens evaluated, there was no signal of varying efficacy with type, dose/dose intensity of bisphosphonate administration. We evaluated the effect of early treatment cessation…
Source: European Journal of CancerCategories: Latest Headlines, Oncologists2Tweet-
More on less. Adjuvant bisphosphonates just a effective with <=6 infusions >=7. De-escalate! #bcsm https://t.co/ntBKcZ60WZ
-
Embark created many expectations. In our P2 trial, an ARSI as mono seems not be the best choice for an unselected mHSPC patients. We must better select patients and try studies for de-intensification strategy too https://t.co/4mVaXh9Uwb @neerajaiims @Silke_Gillessen @ChrisSweens1 https://t.co/xbhR2RRy9F